Novartis Campus and EAACI Congress 2026: Rhapsido Data Highlights
Exploring Medical Innovation in Basel
As a central hub for pharmaceutical research and development, Basel continuously connects global health advancements with local scientific leadership. Among the key highlights shaping current medical discussions are new clinical insights presented at major international scientific gatherings.
Novartis has announced plans to share significant clinical trial findings at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026. The presentations focus on Rhapsido® (remibrutinib) and span multiple immune-mediated conditions, highlighting ongoing developments in immunology.
Key Clinical Findings and Presentations
The upcoming congress presentations feature data from several major studies, including late-breaking oral presentations on chronic inducible urticaria and chronic spontaneous urticaria. According to Novartis, these findings aim to provide deeper scientific evidence regarding BTK inhibition and its potential impact on patient quality of life and treatment experiences.
Visitors interested in learning more about the broader scientific environment and related cultural offerings in the area can browse museums or check the map view to plan their visit. For additional updates and local exhibitions, explore what's available through Musemap.
